Literature DB >> 27847929

The effectiveness of metacognitive training for patients with schizophrenia: a narrative systematic review of studies published between 2009 and 2015.

Daniel Pankowski1, Joachim Kowalski2, Łukasz Gawęda3.   

Abstract

OBJECTIVES: The aim of this paper is to review results of studies on the effectiveness of metacognitive training (MCT) for patients with schizophrenia in reduction of psychotic symptoms and cognitive biases. Furthermore, other variables, like social functioning, insight and neurocognitive functions, are analyzed.
METHODS: Systematic search in databases PubMed, EBSCO, Google Scholar, EMBASE, Cochrane Central Register of Controlled Trials and PsycINFO regarding studies on the effectiveness of the MCT was made. The review included 14 studies published in years 2009-2015, in which design of the study made comparison between MCT group and control group possible.
RESULTS: Combined number of patients in MCT group was 354 and 355 in control group. The largest effect size was obtained for severity of delusions (d < 0.23; 1 >), especially reduction of conviction and distress of delusional beliefs. An effect size regarding negative symptoms reduction was small. Large effect size was observed for insight improvement (d < 0.45; 1.32 >). Positive impact of MCT on cognitive biases severity (d < 0.21; 0.83 >, especially jumping to conclusions) and improvement in some aspects of neurocognitive functions was observed (d < 0.2; 0.63 >). There was no improvement in social functioning of patients in MCT group. Follow-up studies show sustainability in symptoms improvement lasting at least 6 months.
CONCLUSIONS: MCT is an effective form of therapy in reduction of delusions, cognitive biases related to schizophrenia and improvement of insight. Relatively easy accessibility and sustainability of therapeutic effects indicates that MCT can by effectively used in therapy of schizophrenia. To enhance training efficacy, especially in patients' general functioning, combining it with others forms of therapy is to be considered.

Entities:  

Keywords:  cognitive biases; group metacognitive training; schizophrenia

Mesh:

Year:  2016        PMID: 27847929     DOI: 10.12740/PP/59113

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  6 in total

1.  Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes.

Authors:  Juliet Silberstein; Philip D Harvey
Journal:  Cogn Neuropsychiatry       Date:  2018-11-26       Impact factor: 1.871

2.  Efficacy of Metacognitive Training for Patients With Schizophrenia in Psychiatric Emergency Wards: A Pilot Randomized Controlled Trial.

Authors:  Saori Haga; Masayoshi Kobayashi; Ayako Takehara; Kojiro Kawano; Kenji Endo
Journal:  Front Psychol       Date:  2022-04-11

3.  Efficacy of metacognitive training on symptom severity, neurocognition and social cognition in patients with schizophrenia: A single-blind randomized controlled trial.

Authors:  Zita Fekete; Edit Vass; Ramóna Balajthy; Ünige Tana; Attila Csaba Nagy; Barnabás Oláh; Nóra Domján; Ildikó Szabó Kuritárné
Journal:  Scand J Psychol       Date:  2022-04-06

4.  Metacognitive Training Modulates Default-Mode Network Homogeneity During 8-Week Olanzapine Treatment in Patients With Schizophrenia.

Authors:  Xiaoxiao Shan; Rongyuan Liao; Yangpan Ou; Yudan Ding; Feng Liu; Jindong Chen; Jingping Zhao; Wenbin Guo; Yiqun He
Journal:  Front Psychiatry       Date:  2020-03-27       Impact factor: 4.157

5.  The Efficacy of Extended Metacognitive Training on Neurocognitive Function in Schizophrenia: A Randomized Controlled Trial.

Authors:  Can Wang; Yue Chong; Jiechun Zhang; Yili Cao; Yanbo Wang
Journal:  Brain Sci       Date:  2022-03-21

6.  Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia.

Authors:  Xiaoxiao Shan; Rongyuan Liao; Yangpan Ou; Pan Pan; Yudan Ding; Feng Liu; Jindong Chen; Jingping Zhao; Wenbin Guo; Yiqun He
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03-25       Impact factor: 5.270

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.